

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology.

Variable	n	HR	95% CI	p-value
Surgical violation				
No	103	1	-	-
Yes	47	0.8	0.4-1.6	0.57
Prior bladder cancer				
No	120	1	-	-
Yes	30	7.2	3.39-15.66	0.001
Clinical Tumour Stage				
Ta/T1	126	1	-	-
T2-T4	24	0.46	0.19-1.15	0.099
ASA-score				
1	23	1	-	-
2	86	1.3	0.56-2.81	0.59
3+4	41	1.6	0.57-4.54	0.37
Urinary Cytology				
Benign	35	1	-	-
Atypia	38	1.5	0.64-3.56	0.35
Malignant	33	0.9	0.91-6.51	0.81
Low differentiated	16	2.6	0.90-7.25	0.08

Supplemental Table 1. Association between intravesical recurrence-free survival (IVRFS) adjusted for ASA-score (1 vs 2 vs 3/4), prior bladder cancer (no vs yes), clinical tumor stage group (stratified as T1/T1 vs T2-T4 and/or N+) and voided urinary cytology (benign vs atypia/malignant) by Cox proportional hazards. IVR= Intravesical recurrence; SV=Surgical violation.

Variable	n	HR	95% CI	p-value
Surgical violation				
No	103	1	-	-
Yes	47	1.9	1.03-3.7	0.04
Prior bladder cancer				
No	120	1		-
Yes	30	1.9	0.88-3.90	0.105
Clinical Tumour Stage				
Ta/T1	126	1		-
T2-T4	24	1.8	0.92-3.65	0.087
ASA-score				
1	23	1	-	-
2	86	1.3	0.459-3.44	0.656
3+4	41	1.2	0.41-3.80	0.696
Urinary Cytology				
Benign	35	1	-	-
Atypia	38	2.3	0.86-6.17	0.097
Malignant	33	2.4	0.91-6.51	0.078
Low differentiated	16	4.6	1.513-13.87	0.007

Supplemental Table 2. Association disease-specific survival (DSS) adjusted for ASA-score (1 vs 2 vs 3/4), prior bladder cancer (no vs yes), clinical tumor stage group (stratified as T1/T1 vs T2-T4 and/or N+) and voided urinary cytology (benign vs atypia/malignant) by Cox proportional hazards. IVR= Intravesical recurrence; SV=Surgical violation.

Variable	n	HR	95% CI	p-value
Surgical violation				
No	103	1	-	-
Yes	47	1.9	1.21-3.13	0.006
Prior bladder cancer				
No	120	1		-
Yes	36	2.0	1.14-3.40	0.015
Clinical Tumour Stage				
Ta/T1	126	1		-
T2-T4	24	1.08	0.64-1.83	0.767
ASA-score				
1	23	1	-	-
2	86	1.9	0.89-4.26	0.094
3+4	41	2.8	1.21-6.5	0.016
Urinary Cytology				
Benign	35	1	-	-
Atypia	38	2.8	1.47-5.63	0.002
Malignant	33	1.8	0.86-3.60	0.12
Low differentiated	16	4.0	1.87-8.71	0.001

Supplemental Table 3. Association between overall survival (OS) adjusted for ASA-score (1 vs 2 vs 3/4), prior bladder cancer (no vs yes), clinical tumor stage group (stratified as T1/T1 vs T2-T4 and/or N+) and voided urinary cytology (benign vs atypia/malignant) by Cox proportional hazards. IVR= Intravesical recurrence; SV=Surgical violation.